GlassScriptPhysician profile
Jatin K Kadakia
NPI 1831262385
$14,161.86
in general payments reported to CMS, 2019-2025
38 companies · $3,054 in 2025
The $3,054 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,676 · 2020: $1,512 · 2021: $1,690 · 2022: $1,755 · 2023: $1,927 · 2024: $2,549 · 2025: $3,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,201 · Education: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,201.09 |
| Education | $328.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,808.12 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $2,650.48 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $1,079.94 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $965.03 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $937.81 | 2019-2025 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $923.93 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $619.54 | 2019-2025 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Harmony Biosciences LLC | $568.66 | 2021-2025 | Wakix |
| Genzyme Corporation | $513.83 | 2019-2025 | |
| Insmed, INC. | $432.19 | 2020-2025 | Arikayce, Brinsupri |
| Jazz Pharmaceuticals INC. | $373.94 | 2019-2025 | Xywav |
| Viatris Specialty LLC | $247.65 | 2025 | Yupelri |
| Verona Pharma, INC. | $246.83 | 2025 | Ohtuvayre |
| Philips North America LLC | $227.18 | 2019-2023 | |
| Inspire Medical Systems, INC. | $207.91 | 2019-2025 | Inspire |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $177.34 | 2023-2025 | Smartvest |
| Avadel Cns Pharmaceuticals, LLC | $176.49 | 2023-2025 | Lumryz |
| Pfizer INC. | $102.26 | 2020-2025 | |
| Baxter Healthcare | $83.43 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $79.29 | 2025 | Glassia |
| Pulmonx Corporation | $71.88 | 2023-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Circassia INC. | $70.66 | 2019-2020 | |
| Genentech USA, INC. | $67.35 | 2019 | |
| Sanofi-Aventis U.S. LLC | $61.99 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $59.58 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $54.35 | 2023-2025 | Quviviq, Quviviq |
| Paratek Pharmaceuticals, INC. | $50.36 | 2020 | |
| Advanced Respiratory, INC | $49.97 | 2019-2021 | |
| United Therapeutics Corporation | $38.06 | 2025 | Tyvaso |
| Novartis Pharmaceuticals Corporation | $37.43 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.01 | 2025 | |
| Eisai INC. | $27.38 | 2020-2021 | |
| La Jolla Pharmaceutical Company | $26.80 | 2025 | Giapreza |
| Amgen INC. | $24.88 | 2025 | Tezspire |
| 3b Medical, INC. | $24.62 | 2025 | Luna |
| Breas Medical, INC. | $16.09 | 2025 | Vivo 45 Ls |
| Inogen, INC. | $15.90 | 2025 | |
| Merck Sharp & Dohme LLC | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jatin Kadakia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.